Shield Therapeutics PLC
LSE:STX

Watchlist Manager
Shield Therapeutics PLC Logo
Shield Therapeutics PLC
LSE:STX
Watchlist
Price: 10.26 GBX 3.64% Market Closed
Market Cap: £108.9m

Net Margin

-51.2%
Current
Improving
by 302.7%
vs 3-y average of -353.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-51.2%
=
Net Income
£-21.2m
/
Revenue
£41.5m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-51.2%
=
Net Income
GBX-21.2m
/
Revenue
£41.5m

Peer Comparison

Country Company Market Cap Net
Margin
UK
Shield Therapeutics PLC
LSE:STX
104.1m GBP
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Lower than 95% of companies in United Kingdom
Percentile
5th
Based on 3 670 companies
5th percentile
-51.2%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Shield Therapeutics PLC
Glance View

Market Cap
108.9m GBX
Industry
Pharmaceuticals

Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear and currently employs 16 full-time employees. The company went IPO on 2016-02-26. The firm specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The firm's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.

STX Intrinsic Value
9.33 GBX
Overvaluation 9%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-51.2%
=
Net Income
£-21.2m
/
Revenue
£41.5m
What is Shield Therapeutics PLC's current Net Margin?

The current Net Margin for Shield Therapeutics PLC is -51.2%, which is above its 3-year median of -353.9%.

How has Net Margin changed over time?

Over the last 3 years, Shield Therapeutics PLC’s Net Margin has increased from -753.4% to -51.2%. During this period, it reached a low of -905.4% on Dec 31, 2022 and a high of -51.2% on Jun 30, 2025.

Back to Top